Several other research firms also recently commented on HCM. Zacks Investment Research downgraded HUTCHISON CHINA/S from a hold rating to a sell rating in a research report on Thursday, April 11th. HSBC began coverage on HUTCHISON CHINA/S in a research note on Wednesday, March 27th. They issued a buy rating for the company. Finally, Deutsche Bank began coverage on HUTCHISON CHINA/S in a research note on Monday, March 4th. They issued a buy rating and a $26.82 price target for the company. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. HUTCHISON CHINA/S has a consensus rating of Buy and a consensus price target of $26.82.
HUTCHISON CHINA/S stock opened at $26.86 on Monday. The company has a quick ratio of 4.19, a current ratio of 4.33 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $3.56 billion, a price-to-earnings ratio of -47.12 and a beta of 1.04. HUTCHISON CHINA/S has a 12 month low of $20.83 and a 12 month high of $39.68.
HUTCHISON CHINA/S Company Profile
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Featured Story: Calculate Your Return on Investment (ROI)
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.